Lecanemab delayed patients’ worsening by about five months over the course of the 18-month study, according to a spokesperson with the drugmaker Eisai.
- An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening — but the anxiously awaited new data leaves unclear how much difference that might make in people’s lives.that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better treatments of the incurable disease.
The study’s key finding: Those given lecanemab declined more slowly, a difference of not quite half a point on that scale over the 18 months, concluded the research team led by Dr. Christopher van Dyck at Yale University. He said many researchers believe a meaningful improvement would require at least a difference of a full point on that 18-point scale.
“We all understand that this is not a cure and we’re all trying to really grasp what it means to slow Alzheimer’s, because this is a first,” Carrillo said. Also, two deaths have been publicly reported among lecanemab users who also were taking blood-thinning medications for other health problems. Eisai said Tuesday the deaths can’t be attributed to the Alzheimer’s drug.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focusAn experimental Alzheimer's drug slowed cognitive decline in a trial but may carry a risk of dangerous side effects for certain patients
Consulte Mais informação »
Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focusThe 18-month trial enrolled nearly 1,800 participants.
Consulte Mais informação »
DOJ: Bothell drug dealer sentenced 10 years for involvement in 2020 drug ring takedownA Bothell man who was involved in a major drug ring bust in 2020 was sentenced to 10 years in prison on Tuesday, according to the U.S. Department of Justice (DOJ). FOX13
Consulte Mais informação »
Mark Cuban’s prescription drug company in talks with hospitals to fill drug shortagesThe U.S. Food and Drug Administration maintains a list of 185 drugs in short supply.
Consulte Mais informação »
New Alzheimer’s drug shows promise in slowing disease but may contain significant risks, study showsAn experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers report — but it remains unclear how much difference that might make in people’s lives.
Consulte Mais informação »
New Alzheimer’s Drug Shows Positive Results but Side EffectsA new Alzheimer’s drug slowed cognitive decline in a study, but caused brain bleeds and swelling in some patients, furthering debate about its usefulness
Consulte Mais informação »